IL5RA and osteomyelitis: On the other hand, P2 emphasizes the role of early initiation of therapy with an IL-5-/IL-5R-targeting mAb to avoid CS toxicity, as the CS effect on bone reabsorption is a secondary insult to a patient presenting with a pathologic bone fracture from osteomyelitis (29).